Literature DB >> 32925467

Medicare Advantage Chart Reviews Are Associated With Billions in Additional Payments for Some Plans.

David J Meyers1, Amal N Trivedi.   

Abstract

BACKGROUND: In the Medicare Advantage (MA) program, private plans receive capitated payments that are adjusted based on their enrollees' number and type of clinical conditions. Plans have the ability to review charts to identify additional conditions that are not present in claims data, thereby increasing risk-adjusted payments. Recently the Government Accountability Office released a report raising concerns about the use of these chart reviews as a potential tool for upcoding.
OBJECTIVES: To measure the extent to which plans receive additional payments for chart reviews, and the variation in chart reviews across plans. RESEARCH
DESIGN: In this cross-sectional study we use 2015 MA Encounter data to calculate how many additional diagnoses codes were added for each enrollee using chart reviews. We then calculate how these additional diagnosis codes translate to additional reimbursements across plans.
SUBJECTS: A total of 14,021,692 beneficiaries enrolled in 510 MA contracts in 2015. MEASURES: Individual and contract level hierarchical condition category codes, total plan reimbursement.
RESULTS: Chart reviews were associated with a $2.3 billion increase in payments to plans, a 3.7% increase in Medicare spending to MA plans. Just 10% of plans accounted for 42% of the $2.3 billion in additional spending attributed to chart review. Among these plans, the relative increase in risk score from chart review was 17.2%. For-profit plans engaged in chart reviews substantially more frequently than nonprofit plans.
CONCLUSIONS: Given the substantial and highly variable increase in payments attributable to chart review, further investigation of the validity of this practice and its implications for Medicare spending is needed.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 32925467      PMCID: PMC7855237          DOI: 10.1097/MLR.0000000000001412

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   3.178


  8 in total

1.  Risk Adjustment Tools for Learning Health Systems: A Comparison of DxCG and CMS-HCC V21.

Authors:  Todd H Wagner; Anjali Upadhyay; Elizabeth Cowgill; Theodore Stefos; Eileen Moran; Steven M Asch; Peter Almenoff
Journal:  Health Serv Res       Date:  2016-02-03       Impact factor: 3.402

2.  Concentration of Physician Services Across Insurers and Effects on Quality: Early Evidence From Medicare Advantage.

Authors:  W Pete Welch; Aditi P Sen; Andrew B Bindman
Journal:  Med Care       Date:  2019-10       Impact factor: 2.983

3.  Getting What We Pay For: How Do Risk-Based Payments to Medicare Advantage Plans Compare with Alternative Measures of Beneficiary Health Risk?

Authors:  Paul D Jacobs; Richard Kronick
Journal:  Health Serv Res       Date:  2018-05-22       Impact factor: 3.402

4.  Medicare Advantage Checkup.

Authors:  Patricia Neuman; Gretchen A Jacobson
Journal:  N Engl J Med       Date:  2018-11-14       Impact factor: 91.245

5.  How successful is Medicare Advantage?

Authors:  Joseph P Newhouse; Thomas G McGuire
Journal:  Milbank Q       Date:  2014-06       Impact factor: 4.911

6.  How Does Risk Selection Respond to Risk Adjustment? New Evidence from the Medicare Advantage Program.

Authors:  Jason Brown; Mark Duggan; Ilyana Kuziemko; William Woolston
Journal:  Am Econ Rev       Date:  2014-10

7.  Upcoding: Evidence from Medicare on Squishy Risk Adjustment.

Authors:  Michael Geruso; Timothy Layton
Journal:  J Polit Econ       Date:  2020-01-29

8.  Comparison of the Quality of Hospitals That Admit Medicare Advantage Patients vs Traditional Medicare Patients.

Authors:  David J Meyers; Amal N Trivedi; Vincent Mor; Momotazur Rahman
Journal:  JAMA Netw Open       Date:  2020-01-03
  8 in total
  1 in total

1.  Opening the black box: Evaluating the care of people with serious illness in Medicare Advantage.

Authors:  Claire K Ankuda; Lauren J Hunt
Journal:  J Am Geriatr Soc       Date:  2021-06-30       Impact factor: 5.562

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.